New Zealand markets closed
  • NZX 50

    13,093.24
    -32.74 (-0.25%)
     
  • NZD/USD

    0.7153
    -0.0006 (-0.08%)
     
  • NZD/EUR

    0.6145
    -0.0005 (-0.08%)
     
  • ALL ORDS

    7,726.80
    -1.70 (-0.02%)
     
  • ASX 200

    7,415.50
    +0.10 (+0.00%)
     
  • OIL

    83.26
    +0.76 (+0.92%)
     
  • GOLD

    1,798.70
    +16.80 (+0.94%)
     
  • NASDAQ

    15,489.59
    +100.88 (+0.66%)
     
  • FTSE

    7,228.96
    +38.66 (+0.54%)
     
  • Dow Jones

    35,603.08
    -6.26 (-0.02%)
     
  • DAX

    15,597.31
    +124.75 (+0.81%)
     
  • Hang Seng

    26,126.93
    +109.40 (+0.42%)
     
  • NIKKEI 225

    28,804.85
    +96.27 (+0.34%)
     
  • NZD/JPY

    81.3920
    -0.1470 (-0.18%)
     

Here's the Next Blockbuster Vaccine Opportunity for Pfizer

·4-min read
Here's the Next Blockbuster Vaccine Opportunity for Pfizer

Comirnaty, the COVID-19 vaccine marketed by Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX), should rake in $33.5 billion in sales this year. Pfizer also claims the world's second best-selling vaccine. The company won U.S. regulatory approval for a successor product, Prevnar 20, in immunizing adults earlier this summer.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting